IMADSHUREIQIIMAD SHUREIQI8823SHUREIQI, IMADAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1680301Authorship 1692043Authorship 1732641Authorship 1771191Authorship 1818097Authorship 1844414Authorship 1847101Authorship 1893293Authorship 1918933Authorship 19330625Authorship 193452410505781Shureiqi I, Brenner DECurrent opinion in oncologyChemoprevention of epithelial cancers. Curr Opin Oncol. 1999 Sep; 11(5):408-13.Curr Opin Oncol1999-09-01T00:00:001999Chemoprevention of epithelial cancers.11709563McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TSJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001 Nov 15; 19(22):4202-8.J Clin Oncol2001-11-15T00:00:002001Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.12909723Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SMProceedings of the National Academy of Sciences of the United States of AmericaThe 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9968-73.Proc Natl Acad Sci U S A2003-08-08T00:00:002003The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells.17167069Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, Lippman SMFASEB journal : official publication of the Federation of American Societies for Experimental BiologyThe transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J. 2007 Mar; 21(3):743-53.FASEB J2006-12-13T00:00:002006The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer.19198625Zuo X, Morris JS, Broaddus R, Shureiqi IOncogene15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene. 2009 Mar 26; 28(12):1496-505.Oncogene2009-02-09T00:00:00200915-LOX-1 transcription suppression through the NuRD complex in colon cancer cells.22037943Il Lee S, Zuo X, Shureiqi ICancer metastasis reviews15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev. 2011 Dec; 30(3-4):481-91.Cancer Metastasis Rev2011-12-01T00:00:00201115-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?24177031Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GLAmerican journal of physiology. Gastrointestinal and liver physiologyFXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am J Physiol Gastrointest Liver Physiol. 2014 Jan 01; 306(1):G48-58.Am J Physiol Gastrointest Liver Physiol2013-10-31T00:00:002013FXR silencing in human colon cancer by DNA methylation and KRAS signaling.BiostatisticsGastroenterology Hepatology & NutritionGI Medical OncologyGynecological Oncology & Reproductive MedicinePalliative Care & Rehabilitation MedicineSurgical OncologyMD AndersonRUSSELLBROADDUSRUSSELL BROADDUS8814BROADDUS, RUSSELLProfessorDAOYANWEIDAOYAN WEI8946WEI, DAOYANAssistant ProfessorXIANGSHENGZUOXIANGSHENG ZUO8998ZUO, XIANGSHENGAssistant ProfessorJAFFER AAJANIJAFFER A AJANI8473AJANI, JAFFER AProfessorJEAN NICOLASVAUTHEYJEAN NICOLAS VAUTHEY8766VAUTHEY, JEAN NICOLASProfessorPEIYINGYANGPEIYING YANG8795YANG, PEIYINGAssociate Professor6.458780.00418096410research areas6.009720.027910776coauthor of74.687616.748960similar to1180selected publicationsJEFFREYMORRISJEFFREY MORRIS8907MORRIS, JEFFREYProfessorANIL KSOODANIL K SOOD9048SOOD, ANIL KProfessorGEORGE JCHANGGEORGE J CHANG9201CHANG, GEORGE JProfessorAuthorship 2166731Authorship 2169131Authorship 2178704Authorship 2190011Authorship 2264413Authorship 2272235Authorship 2328496Authorship 2349411210506115Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DECarcinogenesisDecreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis. 1999 Oct; 20(10):1985-95.Carcinogenesis1999-10-01T00:00:001999Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers.10904086Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SMJournal of the National Cancer Institute15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000 Jul 19; 92(14):1136-42.J Natl Cancer Inst2000-07-19T00:00:00200015-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells.11156377Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SMCancer research15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000 Dec 15; 60(24):6846-50.Cancer Res2000-12-15T00:00:00200015-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.11352853Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, Peters-Golden M, Rock CL, Boland CR, Brenner DECancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyColonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001 May; 10(5):447-53.Cancer Epidemiol Biomarkers Prev2001-05-01T00:00:002001Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.18421052Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng CJournal of clinical oncology : official journal of the American Society of Clinical OncologySystematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5.J Clin Oncol2008-04-20T00:00:002008Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.18799463Zuo X, Morris JS, Shureiqi IThe Journal of biological chemistryChromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. J Biol Chem. 2008 Nov 14; 283(46):31341-7.J Biol Chem2008-09-17T00:00:002008Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells.22895552Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim JInternational journal of oncologyArachidonic acid metabolism in human prostate cancer. Int J Oncol. 2012 Oct; 41(4):1495-503.Int J Oncol2012-08-10T00:00:002012Arachidonic acid metabolism in human prostate cancer.24315563Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CHInternational journal of radiation oncology, biology, physicsPreoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.Int J Radiat Oncol Biol Phys2013-12-05T00:00:002013Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.Authorship 2416221Authorship 2425691Authorship 2428281Authorship 2462644Authorship 2478986Authorship 2485488Authorship 2520877Authorship 2557511Authorship 25674011Authorship 258832210789490Shureiqi I, Reddy P, Brenner DECritical reviews in oncology/hematologyChemoprevention: general perspective. Crit Rev Oncol Hematol. 2000 Mar; 33(3):157-67.Crit Rev Oncol Hematol2000-03-01T00:00:002000Chemoprevention: general perspective.11406566Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SMCancer researchNonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res. 2001 Jun 15; 61(12):4879-84.Cancer Res2001-06-15T00:00:002001Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression.11504772Shureiqi I, Cooksley CD, Morris J, Soliman AS, Levin B, Lippman SMJournal of the National Cancer InstituteEffect of age on risk of second primary colorectal cancer. J Natl Cancer Inst. 2001 Aug 15; 93(16):1264-6.J Natl Cancer Inst2001-08-15T00:00:002001Effect of age on risk of second primary colorectal cancer.15574791Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SMCancer researchThe histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. 2004 Dec 01; 64(23):8778-81.Cancer Res2004-12-01T00:00:002004The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.16288226Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi IOncogeneOxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene. 2006 Feb 23; 25(8):1225-41.Oncogene2006-02-23T00:00:002006Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity.17011176Yang P, Chan D, Felix E, Madden T, Klein RD, Shureiqi I, Chen X, Dannenberg AJ, Newman RAProstaglandins, leukotrienes, and essential fatty acidsDetermination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids. 2006 Dec; 75(6):385-95.Prostaglandins Leukot Essent Fatty Acids2006-09-29T00:00:002006Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids.19436036Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM, Shureiqi IJournal of the National Cancer InstituteTargeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst. 2009 May 20; 101(10):762-7.J Natl Cancer Inst2009-05-12T00:00:002009Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis.21372027Shureiqi I, Baron JACancer prevention research (Philadelphia, Pa.)Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila). 2011 Mar; 4(3):296-8.Cancer Prev Res (Phila)2011-03-01T00:00:002011Curcumin chemoprevention: the long road to clinical translation.22472308Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi IJournal of the National Cancer InstituteEffects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst. 2012 May 02; 104(9):709-16.J Natl Cancer Inst2012-04-02T00:00:002012Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice.22960430Zuo X, Shureiqi IProstaglandins & other lipid mediatorsEicosanoid profiling in colon cancer: emergence of a pattern. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:139-43.Prostaglandins Other Lipid Mediat2012-09-01T00:00:002012Eicosanoid profiling in colon cancer: emergence of a pattern.Authorship 2654951Authorship 2655781Authorship 2658802Authorship 2671693Authorship 27048011Authorship 27165311Authorship 271672811861401Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, Lotan R, Lippman SMCancer researchGATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res. 2002 Feb 15; 62(4):1178-83.Cancer Res2002-02-15T00:00:002002GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells.11870511Shureiqi I, Cantor SB, Lippman SM, Brenner DE, Chernew ME, Fendrick AMBritish journal of cancerClinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer. 2002 Jan 21; 86(2):226-32.Br J Cancer2002-01-21T00:00:002002Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.15547171Duffield-Lillico AJ, Shureiqi I, Lippman SMJournal of the National Cancer InstituteCan selenium prevent colorectal cancer? A signpost from epidemiology. J Natl Cancer Inst. 2004 Nov 17; 96(22):1645-7.J Natl Cancer Inst2004-11-17T00:00:002004Can selenium prevent colorectal cancer? A signpost from epidemiology.16166323Deguchi A, Xing SW, Shureiqi I, Yang P, Newman RA, Lippman SM, Feinmark SJ, Oehlen B, Weinstein IBCancer researchActivation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Res. 2005 Sep 15; 65(18):8442-7.Cancer Res2005-09-15T00:00:002005Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells.21881028Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi ICancer prevention research (Philadelphia, Pa.)Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prev Res (Phila). 2011 Dec; 4(12):1961-72.Cancer Prev Res (Phila)2011-08-31T00:00:002011Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion.23073998Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RAMolecular carcinogenesisCellular location and expression of Na+, K+ -ATPase a subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog. 2014 Apr; 53(4):253-63.Mol Carcinog2012-10-16T00:00:002012Cellular location and expression of Na+, K+ -ATPase a subunits affect the anti-proliferative activity of oleandrin.24385213Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Est?cio MR, Issa JPCancer researchFusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014 Mar 01; 74(5):1311-8.Cancer Res2014-01-02T00:00:002014Fusobacterium in colonic flora and molecular features of colorectal carcinoma.Authorship 2731381Authorship 2735989Authorship 27490110Authorship 2754231216357157Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SMCancer researchThe critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005 Dec 15; 65(24):11486-92.Cancer Res2005-12-15T00:00:002005The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis.18388920Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi IMolecular therapy : the journal of the American Society of Gene TherapyTherapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther. 2008 May; 16(5):886-92.Mol Ther2008-03-18T00:00:002008Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.23332604Lynch PM, Morris JS, Ross WA, Rodriguez-Bigas MA, Posadas J, Khalaf R, Weber DM, Sepeda VO, Levin B, Shureiqi IGastrointestinal endoscopyGlobal quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool. Gastrointest Endosc. 2013 Mar; 77(3):455-63.Gastrointest Endosc2013-01-18T00:00:002013Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.24681603Zuo X, Xu M, Yu J, Wu Y, Moussalli MJ, Manyam GC, Lee SI, Liang S, Gagea M, Morris JS, Broaddus RR, Shureiqi IJournal of the National Cancer InstitutePotentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-d/? overexpression. J Natl Cancer Inst. 2014 Apr; 106(4):dju052.J Natl Cancer Inst2014-03-28T00:00:002014Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-d/? overexpression.Authorship 2887707Authorship 2892993Authorship 29538010Authorship 3053708Authorship 305618924634093Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W, Shureiqi ICancer medicine15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1a expression in human colon cancer cells. Cancer Med. 2014 Jun; 3(3):472-84.Cancer Med2014-03-15T00:00:00201415-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1a expression in human colon cancer cells.24756833Bolonesi RM, Rogers JE, Shureiqi IJournal of gastrointestinal cancerA case report--treatment of metastatic colorectal cancer in a patient on hemodialysis. J Gastrointest Cancer. 2014 Dec; 45 Suppl 1:161-5.J Gastrointest Cancer2014-12-01T00:00:002014A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.25713055Mao F, Xu M, Zuo X, Yu J, Xu W, Moussalli MJ, Elias E, Li HS, Watowich SS, Shureiqi IFASEB journal : official publication of the Federation of American Societies for Experimental Biology15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway. FASEB J. 2015 Jun; 29(6):2359-70.FASEB J2015-02-24T00:00:00201515-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway.26062928Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng CInvestigational new drugsPhase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015 Aug; 33(4):977-84.Invest New Drugs2015-06-12T00:00:002015Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.26100521Ford NA, Rossi EL, Barnett K, Yang P, Bowers LW, Hidaka BH, Kimler BF, Carlson SE, Shureiqi I, deGraffenried LA, Fabian CJ, Hursting SDCancer prevention research (Philadelphia, Pa.)Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer. Cancer Prev Res (Phila). 2015 Sep; 8(9):796-806.Cancer Prev Res (Phila)2015-06-22T00:00:002015Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.74Professor10Assistant Professor14Associate Professor20570882Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SMCancer prevention research (Philadelphia, Pa.)Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Phila). 2010 Jul; 3(7):829-38.Cancer Prev Res (Phila)2010-06-22T00:00:002010Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis.Authorship 851192Authorship 862159Authorship 863885Authorship 864756Authorship 865336Investigational New DrugsPhase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancerCancer Prevention ResearchOmega-3-acid ethyl esters block the protumorigenic effects of obesity in mouse models of postmenopausal basal-like and claudin-low breast cancer. Cancer Prevention Research. 8:796-806.Omega-3-acid ethyl esters block the protumorigenic effects of obesity in mouse models of postmenopausal basal-like and claudin-low breast cancerCancer DiscoveryPhase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF<sup>V600E</sup> mutation. Cancer Discovery. 6:1352-1365.Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF<sup>V600E</sup> mutationProstaglandins and Other Lipid MediatorsALOX15 as a suppressor of inflammation and cancer. Prostaglandins and Other Lipid Mediators. ALOX15 as a suppressor of inflammation and cancerAnnals of OncologyUtility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Annals of Oncology. 27:1068-1074.Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials18198215Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi IFASEB journal : official publication of the Federation of American Societies for Experimental Biology15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J. 2008 Jun; 22(6):1981-92.FASEB J2008-01-15T00:00:00200815-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation.D047494Chemicals & Drugs26550.934258PPAR deltaD001093Chemicals & Drugs29900.938809Arachidonate 15-LipoxygenaseD015179Disorders68435650.327219Colorectal NeoplasmsD011125Disorders842210.863496Adenomatous Polyposis ColiAuthorship 90588611Authorship 9086296Authorship 90949313Authorship 91185614Authorship 9134179Authorship 92178619Authorship 9225216Authorship 9260628Authorship 9276047Authorship 9286921Authorship 9330554Authorship 9338412Authorship 940266627045102Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz SAnnals of oncology : official journal of the European Society for Medical OncologyUtility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016 06; 27(6):1068-1074.Ann Oncol2016-02-18T00:00:002016Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.27048107Sak ME, Alanbay I, Rodriguez A, Gokaslan T, Borahay M, Shureiqi I, Kilic GSEuropean journal of gynaecological oncologyThe role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas. Eur J Gynaecol Oncol. 2016; 37(1):36-40.Eur J Gynaecol Oncol2016-01-01T00:00:002016The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas.27729313Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz SCancer discoveryPhase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365.Cancer Discov2016-10-11T00:00:002016Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.28267766Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz SPloS oneAssociation of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345.PLoS One2017-03-07T00:00:002017Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.28178489Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi IMolecular therapy : the journal of the American Society of Gene TherapyTherapeutic Molecular Targetingof 15-Lipoxygenase-1 in Colon Cancer. Mol Ther. 2008 May; 16(5):886-892.Mol Ther2016-12-08T00:00:002016Therapeutic Molecular Targetingof 15-Lipoxygenase-1 in Colon Cancer.28089732Tian R, Zuo X, Jaoude J, Mao F, Colby J, Shureiqi IProstaglandins & other lipid mediatorsALOX15 as a suppressor of inflammation and cancer: Lost in the link. Prostaglandins Other Lipid Mediat. 2017 09; 132:77-83.Prostaglandins Other Lipid Mediat2017-01-13T00:00:002017ALOX15 as a suppressor of inflammation and cancer: Lost in the link.28097239Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi IJCI insightMetastasis regulation by PPARD expression in cancer cells. JCI Insight. 2017 01 12; 2(1):e91419.JCI Insight2017-01-12T00:00:002017Metastasis regulation by PPARD expression in cancer cells.28424412Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari AOncotargetFBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.Oncotarget2017-06-13T00:00:002017FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.28850629Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris VPloS oneClinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.PLoS One2017-08-29T00:00:002017Clinical utility of circulating cell-free DNA in advanced colorectal cancer.29263155Shureiqi ICancer prevention research (Philadelphia, Pa.)Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets? Cancer Prev Res (Phila). 2018 01; 11(1):1-3.Cancer Prev Res (Phila)2017-12-19T00:00:002017Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?29934822Colby JK, Jaoude J, Liu F, Shureiqi ICancer metastasis reviewsOxygenated lipid signaling in tumor-associated macrophages-focus on colon cancer. Cancer Metastasis Rev. 2018 09; 37(2-3):289-315.Cancer Metastasis Rev2018-09-01T00:00:002018Oxygenated lipid signaling in tumor-associated macrophages-focus on colon cancer.30332892Wang L, Shureiqi I, Stroehlein JR, Wei DExpert opinion on therapeutic targetsNovel and emerging innate immune therapeutic targets for pancreatic cancer. Expert Opin Ther Targets. 2018 12; 22(12):977-981.Expert Opin Ther Targets2018-10-24T00:00:002018Novel and emerging innate immune therapeutic targets for pancreatic cancer.30373124Liu Y, Colby JK, Zuo X, Jaoude J, Wei D, Shureiqi IInternational journal of molecular sciencesThe Role of PPAR-d in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. Int J Mol Sci. 2018 Oct 26; 19(11).Int J Mol Sci2018-10-26T00:00:002018The Role of PPAR-d in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor.D003110Disorders48913880.543347Colonic NeoplasmsPathologyAuthorship 9424891830679176Liu Y, Deguchi Y, Tian R, Wei D, Wu L, Chen W, Xu W, Xu M, Liu F, Gao S, Jaoude JC, Chrieki SP, Moussalli MJ, Gagea M, Morris J, Broaddus RR, Zuo X, Shureiqi ICancer researchPleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019 03 01; 79(5):954-969.Cancer Res2019-01-24T00:00:002019Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion.Authorship 9433032530885780Zuo X, Deguchi Y, Xu W, Liu Y, Li HS, Wei D, Tian R, Chen W, Xu M, Yang Y, Gao S, Jaoude JC, Liu F, Chrieki SP, Moussalli MJ, Gagea M, Sebastian MM, Zheng X, Tan D, Broaddus R, Wang J, Ajami NJ, Swennes AG, Watowich SS, Shureiqi IGastroenterologyPPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology. 2019 07; 157(1):163-178.Gastroenterology2019-03-15T00:00:002019PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice.23041232Xu M, Zuo X, Shureiqi IBiochemical pharmacologyTargeting peroxisome proliferator-activated receptor-?/d in colon cancer: how to aim? Biochem Pharmacol. 2013 Mar 01; 85(5):607-611.Biochem Pharmacol2012-10-04T00:00:002012Targeting peroxisome proliferator-activated receptor-?/d in colon cancer: how to aim?Authorship 953744931406299Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz SBritish journal of cancerSignet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.Br J Cancer2019-08-13T00:00:002019Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.Authorship 977263732008976Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XSClinical colorectal cancerPatient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2.Clin Colorectal Cancer2019-10-23T00:00:002019Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer.Authorship 994372432665092J?come AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng CClinical colorectal cancerFOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.Clin Colorectal Cancer2020-06-05T00:00:002020FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.Authorship 9974051632814052Liu F, Zuo X, Liu Y, Deguchi Y, Moussalli MJ, Chen W, Yang P, Wei B, Tan L, Lorenzi PL, Gao S, Jaoude JC, Mehdizadeh A, Valentin LA, Wei D, Shureiqi ICell reportsSuppression of Membranous LRP5 Recycling, Wnt/?-Catenin Signaling, and Colon Carcinogenesis by 15-LOX-1 Peroxidation of Linoleic Acid in PI3P. Cell Rep. 2020 08 18; 32(7):108049.Cell Rep2020-08-18T00:00:002020Suppression of Membranous LRP5 Recycling, Wnt/?-Catenin Signaling, and Colon Carcinogenesis by 15-LOX-1 Peroxidation of Linoleic Acid in PI3P.Authorship 1018139333965356Leung M, Rogers JE, Shureiqi IClinical colorectal cancerUse of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant. Clin Colorectal Cancer. 2021 09; 20(3):273-278.Clin Colorectal Cancer2021-04-06T00:00:002021Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.Authorship 1024612934235345Cata JP, Pati?o M, Lacagnina MJ, Li J, Gorur A, Agudelo-Jimenez R, Wei B, Hagberg CA, Dougherty PM, Shureiqi I, Yang P, Grace PMPain reportsA rat model to investigate quality of recovery after abdominal surgery. Pain Rep. 2021 Jul-Aug; 6(2):e943.Pain Rep2021-06-30T00:00:002021A rat model to investigate quality of recovery after abdominal surgery.Authorship 1031078734610992Yang P, Zuo X, Advani S, Wei B, Malek J, Day RS, Shureiqi ICancer prevention research (Philadelphia, Pa.)Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis. Cancer Prev Res (Phila). 2022 04 01; 15(4):217-223.Cancer Prev Res (Phila)2022-04-01T00:00:002022Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis.Authorship 10386677Authorship 10388473Authorship 1039914535314378Powell RT, Moussalli MJ, Guo L, Bae G, Singh P, Stephan C, Shureiqi I, Davies PJSLAS discovery : advancing life sciences R & DdeepOrganoid: A brightfield cell viability model for screening matrix-embedded organoids. SLAS Discov. 2022 04; 27(3):175-184.SLAS Discov2022-03-18T00:00:002022deepOrganoid: A brightfield cell viability model for screening matrix-embedded organoids.35163565Pudakalakatti S, Titus M, Enriquez JS, Ramachandran S, Zacharias NM, Shureiqi I, Liu Y, Yao JC, Zuo X, Bhattacharya PKInternational journal of molecular sciencesIdentifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. Int J Mol Sci. 2022 Jan 31; 23(3).Int J Mol Sci2022-01-31T00:00:002022Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors.35332152Kapalczynska M, Lin M, Maertzdorf J, Heuberger J, Muellerke S, Zuo X, Vidal R, Shureiqi I, Fischer AS, Sauer S, Berger H, Kidess E, Mollenkopf HJ, Tacke F, Meyer TF, Sigal MNature communicationsBMP feed-forward loop promotes terminal differentiation in gastric glands and is interrupted by H. pylori-driven inflammation. Nat Commun. 2022 03 24; 13(1):1577.Nat Commun2022-03-24T00:00:002022BMP feed-forward loop promotes terminal differentiation in gastric glands and is interrupted by H. pylori-driven inflammation.Authorship 10459181935562376Liu Y, Deguchi Y, Wei D, Liu F, Moussalli MJ, Deguchi E, Li D, Wang H, Valentin LA, Colby JK, Wang J, Zheng X, Ying H, Gagea M, Ji B, Shi J, Yao JC, Zuo X, Shureiqi INature communicationsRapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARd. Nat Commun. 2022 05 13; 13(1):2665.Nat Commun2022-05-13T00:00:002022Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARd.Authorship 10613461Authorship 105709619Authorship 1055222636219239Ghosh J, Schultz BM, Chan J, Wultsch C, Singh R, Shureiqi I, Chow S, Doymaz A, Varriano S, Driscoll M, Muse J, Kleiman FE, Krampis K, Issa JJ, Sapienza CCancer prevention research (Philadelphia, Pa.)Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer. Cancer Prev Res (Phila). 2022 11 01; 15(11):755-766.Cancer Prev Res (Phila)2022-11-01T00:00:002022Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer.36239938Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang SJAMA network openAssociation of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open. 2022 10 03; 5(10):e2236357.JAMA Netw Open2022-10-03T00:00:002022Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.36047054Shureiqi ICancer prevention research (Philadelphia, Pa.)Aspirin for Colorectal Cancer Prevention: Age Matters. Cancer Prev Res (Phila). 2022 09 01; 15(9):565-567.Cancer Prev Res (Phila)2022-09-01T00:00:002022Aspirin for Colorectal Cancer Prevention: Age Matters.Authorship 10791841437572185Liu Y, Wei D, Deguchi Y, Xu W, Tian R, Liu F, Xu M, Mao F, Li D, Chen W, Valentin LA, Deguchi E, Yao JC, Shureiqi I, Zuo XGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationPPARd dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer. 2023 Nov; 26(6):904-917.Gastric Cancer2023-08-12T00:00:002023PPARd dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment.true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor23796952Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gaf? R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GAGenome researchCCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013 Sep; 23(9):1446-61.Genome Res2013-06-24T00:00:002013CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.